Zimbabwe leads Africa’s first human trial of T-Cell HIV vaccineZIMBABWE has launched a ground-breaking HIV vaccine trial, with scientists seeking ways to strengthen the immune system’s response to the virus.
An African-led study will evaluate whether the vaccine is safe and prompts an immune response in both HIV-positive and HIV-negative adults.
Mutala Trust’s Infectious disease research laboratory is now the launch pad for Africa’s first-ever HIV vaccine trial.
The development opens a new chapter in the country’s battle against HIV, driven by African scientists for our communities.
“We are working with a group of collaborators globally, as well as centred in Africa, to develop and test a novel HIV vaccine. What is interesting about this vaccine is that it is focused on the parts of the virus that are constrained, either by structure or function, and they have less room to mutate. Part of the problem with HIV has been the amount of mutation that occurs in the virus, making it difficult to make an HIV vaccine. So the idea behind this one is targeting key regions in the virus,” Mutala Trust’s Executive Director, Professor Tariro Makadzange noted.
“For many decades, as scientists and clinicians, we have been working on a vaccine, so our primary goal is to develop a vaccine that can prevent HIV. We also want to develop a vaccine that induces immune responses in people living with HIV so that we can redirect their immune response and better control HIV infection.”
Mutala Trust Medical Officer, Dr Constantine Mutata, reports that eight participants have already been enrolled across the African sites.
“For this HIV vaccine trial, the target is to enrol 120 participants. That is for all three sites, which is the Mutala site and the two sites in South Africa. So far, we have enrolled eight participants, and the age groups are from 18 to 50. We are enrolling both people who are living with HIV and those living without HIV. We are going to be following these participants up for about 19 months, and results will take longer because there will be time for analysis. We do have the capacity, and people who are experienced enough to do the research and laboratory testing.”
With this being the first time Africans are participating in a Phase 1 vaccine trial, the question on everyone’s mind is, are we being used as guinea pigs?
“It is tragic that people say that because in reality, only 2% of clinical trials happen in Africa, so it is the total opposite. As Africans, we are excluded from research. We are about 20% of the world’s population, and only 2% of trials happen in Africa, and that is the narrative we need to change. If we, as Africans, are not driving the science, then we are waiting for Americans and Europeans to develop vaccines and therapies for us. So it is absolutely essential for us as Africans to be part of the science and part of the development,” Professor Makadzange said.
“The nice thing about this vaccine is we, as Zimbabwean scientists, are the clinical leads. We have designed and developed the way the study is being done. This is a nice example of science for Africans by Africans. The reality is that we are not the guinea pigs, we are waiting for people elsewhere to volunteer and for the drugs to be developed. This time, we want to be the ones who are developing the science, developing the innovation.”
The HIV vaccine trial is more than a scientific milestone, it is a symbol of Zimbabwe’s leadership, resilience and innovation in the fight against HIV
Info News
Debt Consolidation Loans: Are They Worth It?
Debt can become overwhelming when you are juggling multiple credit cards, personal loans, medical bills, and high-interest payments. A debt consolidation loan may help simplify your finances by combining several debts into one monthly payment.
rnrn
The main goal of debt consolidation is to get a lower interest rate, reduce payment stress, and create a clearer payoff plan. Instead of making several payments to different lenders, you make one payment to one lender.
rnrn
Debt consolidation may be worth it if you qualify for a lower interest rate than what you are currently paying. This is especially helpful for credit card debt, which often has high interest rates.
rnrn
However, debt consolidation is not magic. It does not erase your debt. It only restructures it. If you continue using credit cards after consolidating, you may end up with even more debt.
rnrn
Before applying, check the loan’s interest rate, fees, repayment term, monthly payment, and total cost. A lower monthly payment may sound good, but if the loan term is much longer, you may pay more interest over time.
rnrn
Your credit score affects your options. People with strong credit usually qualify for better rates. If your credit score is low, you may receive high-interest offers that do not actually save money.
rnrn
Debt consolidation can also help your credit if you make payments on time and reduce credit card balances. But missing payments can damage your credit further.
rnrn
Other options may include credit counseling, balance transfer cards, debt management plans, or budgeting changes.
rnrn
A debt consolidation loan is worth considering if it lowers your interest, creates a realistic payoff plan, and helps you stop relying on credit cards.
rnrn
The key is discipline. Consolidation works best when you combine it with better spending habits and a serious plan to become debt-free.
rn
Expert Legal Insight
Navigating complex legal situations after an accident requires more than basic knowledge—it demands strategic expertise. High-value cases such as truck accidents, construction injuries, and personal injury claims often involve multiple parties, insurance negotiations, and strict deadlines. Understanding your rights early can make a significant difference in the outcome of your case.
rnrn
Many individuals searching for terms like “top personal injury lawyer near me” or “high settlement accident attorney” are looking for reliable guidance. Consulting a qualified legal professional can help you build a strong case, maximize compensation, and avoid common mistakes that reduce claim value.
rn
